Ffcm LLC increased its stake in shares of Medtronic plc. (NYSE:MDT) by 22.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 58,751 shares of the medical technology company’s stock after acquiring an additional 10,940 shares during the period. Ffcm LLC’s holdings in Medtronic were worth $4,745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Motco grew its stake in Medtronic by 8.7% during the 2nd quarter. Motco now owns 1,239 shares of the medical technology company’s stock worth $110,000 after buying an additional 99 shares during the last quarter. Quadrant Capital Group LLC grew its stake in Medtronic by 21.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock worth $114,000 after buying an additional 290 shares during the last quarter. Blue Chip Partners Inc. bought a new position in Medtronic during the 3rd quarter worth $118,000. Barrett Asset Management LLC grew its stake in Medtronic by 856.0% during the 4th quarter. Barrett Asset Management LLC now owns 1,826 shares of the medical technology company’s stock worth $147,000 after buying an additional 1,635 shares during the last quarter. Finally, Westwood Holdings Group Inc. bought a new position in Medtronic during the 2nd quarter worth $151,000. Hedge funds and other institutional investors own 81.91% of the company’s stock.

Medtronic plc. (MDT) opened at $81.86 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.05 and a current ratio of 2.40. Medtronic plc. has a 12-month low of $76.51 and a 12-month high of $89.72. The stock has a market capitalization of $108,577.60, a price-to-earnings ratio of 22.43, a price-to-earnings-growth ratio of 2.21 and a beta of 0.93.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.08. The business had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The company’s revenue was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.12 earnings per share. sell-side analysts expect that Medtronic plc. will post 4.76 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 19th. Stockholders of record on Friday, December 29th were issued a $0.46 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $1.84 annualized dividend and a dividend yield of 2.25%. Medtronic’s dividend payout ratio (DPR) is 50.41%.

A number of brokerages recently commented on MDT. Royal Bank of Canada restated an “outperform” rating and set a $92.00 price objective on shares of Medtronic in a research note on Wednesday. SunTrust Banks restated a “buy” rating and set a $96.00 price objective on shares of Medtronic in a research note on Friday, November 3rd. Stifel Nicolaus upped their price objective on Medtronic from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Wednesday, November 22nd. Argus upgraded Medtronic from a “hold” rating to a “buy” rating and upped their price objective for the stock from $81.27 to $95.00 in a research note on Tuesday, December 12th. They noted that the move was a valuation call. Finally, Oppenheimer restated a “buy” rating and set a $94.00 price objective on shares of Medtronic in a research note on Wednesday, November 22nd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $90.45.

In other news, EVP Hooman Hakami sold 26,158 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $85.00, for a total value of $2,223,430.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.82, for a total value of $1,325,120.00. Following the completion of the sale, the executive vice president now owns 88,818 shares of the company’s stock, valued at approximately $7,355,906.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,684 shares of company stock valued at $10,318,276. Insiders own 0.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Medtronic plc. (MDT) Shares Bought by Ffcm LLC” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/02/15/medtronic-plc-mdt-shares-bought-by-ffcm-llc.html.

About Medtronic

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.